ADC Therapeutics SA Net Profit Margin 2019-2023 | ADCT
ADC Therapeutics SA net profit margin from 2019 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
| ADC Therapeutics SA Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-03-31 |
$0.18B |
$-0.20B |
-108.79% |
| 2022-12-31 |
$0.21B |
$-0.16B |
-74.64% |
| 2022-09-30 |
$0.16B |
$-0.17B |
-106.41% |
| 2022-06-30 |
$0.09B |
$-0.19B |
-201.08% |
| 2022-03-31 |
$0.08B |
$-0.20B |
-245.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.192B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
